For today, tomorrow, and the days to come
People featured are compensated by Gilead.
For today, tomorrow, and the days to come
People featured are compensated by Gilead.
For today, tomorrow, and the days to come
People featured are compensated by Gilead.
For today, tomorrow, and the days to come
People featured are compensated by Gilead.
Learn More About Key Patient Populations
Treatment Experienced and Not Virologically Suppressed
Real-World Data: In Treatment-Naïve and Treatment-Experienced Adults, Including Individuals With ART History and Not Virologically Suppressed
People With HIV Aged 50 and Older
7 YEARS AS THE #1 PRESCRIBED* REGIMEN FOR PEOPLE STARTING AND SWITCHING HIV-1 TREATMENT WITH NEARLY 500,000 PWH† IN THE US ON THERAPY1
Fueled by the power of bictegravir1
SOURCE: IQVIA LAAD, August 2018 through July 2025*
Hear from key opinion leaders, Joel E. Gallant, MD, MPH, and Calvin J. Cohen, MD, MSc, as they discuss the events that shaped the way providers approach HIV treatment. Dr. Cohen is an employee of Gilead. Dr. Gallant is a former employee of Gilead.
See Dr. Joel Gallant and Dr. Calvin Cohen discuss more HIV topics:
*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period of August 2018 through July 2025. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.
†This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for July 2025. IQVIA expressly reserves all rights, including rights to copying, distribution, and republication.
DHHS, US Department of Health and Human Services; FDA, US Food and Drug Administration; PWH, people with HIV.
DOVATO® is a trademark of the ViiV Healthcare group of companies.
CABENUVA® is a trademark of the ViiV Healthcare group of companies.
Reference:
- Data on file. Gilead Sciences, Inc.